Mountain State Medical Policy Bulletin |
Section: | Injections |
Number: | I-14 |
Topic: | Intravenous Immune Globulin |
Effective Date: | January 1, 2009 |
Issued Date: | January 5, 2009 |
Date Last Reviewed: | 11/2008 |
Indications and Limitations of Coverage
Coverage for Intravenous Immune Globulin (IVIG) is determined according to individual or group customer benefits. This policy only addresses non-specific pooled preparations of intravenous immune globulin. The policy does not address other immunoglobulin preparations that are specifically used for passive immunization to prevent or attenuate infection with specific viral diseases. Intravenous immune globulin is indicated only if standard therapies have failed, become intolerable, or are contraindicated. Intravenous immune globulin is eligible for the conditions listed below:
Intravenous immunoglobulin is considered not medically necessary and, therefore, not covered as a treatment of relapsing/remitting multiple sclerosis. A participating, preferred, or network provider cannot bill the member for the denied service. The latest technology assessment published by the American Academy of Neurology on therapies for multiple sclerosis offered the following recommendations regarding intravenous immunoglobulin:
Intravenous immune globulin administered for conditions other than those referenced above should be denied as not medically necessary and, therefore, not covered. A participating, preferred, or network provider cannot bill the member for the denied service. Description Immune globulin is one of five closely-related proteins found in the human body. These proteins are capable of acting as antibodies. Gammaglobulin is an intravenous or intramuscular drug which has IgG antibodies and is used for the prevention and treatment of specific disease. Intravenous immune globulin (IVIG) is an antibody-containing solution obtained from the pooled plasma of healthy blood donors, containing antibodies to greater than 10 million antigens. |
|
90283 | 90284 | 90291 | J0850 | J1459 | J1561 |
J1562 | J1566 | J1568 | J1569 | J1571 | J1572 |
J1573 | J2791 |
Under the Federal Employee Program, all services that utilize FDA-approved drugs, devices, or biological products are eligible when intended for the treatment of a serious or life-threatening condition and when medically necessary and appropriate for the patient's condition. |
Treatment of Multiple Sclerosis: Recent Trials and Future Perspectives, Current Opinion in Neurology, Vol. 12, No. 3, 06/99 Immune Globulin Intravenous (Human), USPDI - Vol. I, Edition 26, 2006, Micromedex, Inc. Intravenous Immune Globulin Therapy, National Blue Cross Blue Shield Association Medical Policy Reference Manual, Policy No. 8.01.05, issued April 2005 CSL Behring LLC, Immune Globulin Intravenous (Human), 10% Liquid Privigen™ US package insert, Kankakee, IL: CSL Behring LLC, July, 2007 |
[Version 008 of I-14] |
[Version 007 of I-14] |
[Version 006 of I-14] |
[Version 005 of I-14] |
[Version 004 of I-14] |
[Version 003 of I-14] |
[Version 002 of I-14] |
[Version 001 of I-14] |